Abstract: Objective Neuroinflammation with microglial activation has been implicated to have a strong association with the progressive dopaminergic neuronal loss in Parkinson's disease (PD). The present study was undertaken to evaluate the activation profile of microglia in 1-methyl-4-phenyl pyridinium (MPP 
Introduction
Parkinson's disease (PD) is one of the most common age-related neurodegenerative diseases [1] . Clinically, most patients suffer from slowness of movement, rest tremor, rigidity, and disturbances in balance. Pathologically, it is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra (SN) [2, 3] . Although symptomatic treatments of PD are of proven efficacy, no drugs have been established to have a clinically validated effect on slowing down its progression [4, 5] . Better understanding of these processes leading to progressive dopaminergic neuronal loss may provide effective targets for the design of novel therapeutics to PD. Neuroinflammation have currently been implicated as a driving force in PD pathogenesis [6] . Microglia is suspected to play a major role in this process. As constitutive immune cells in the brain, microglia is sensitive to even minor disturbances in central nervous system (CNS) homeostasis and become readily activated in response to abnormal stimula-tion [7] . Uncontrolled activation of microglia may cause direct toxicity to neurons by releasing various cytotoxic compounds [8] . Activated microglia have been found not only in post-mortem PD brain, but also in various PD models [9] [10] [11] .
Inhibition of microglia-mediated neuroinflammation, therefore, might become a promising therapeutic strategy in PD [12] . We focused on triptolide, an active component derived from the traditional Chinese medicinal plant Tripterygium Wilfordii Hook F (TWHF), which has anti-inflammatory and immunosuppressive activities [13] [14] [15] . In the CNS, triptolide is capable of blocking lipopolysaccharide (LPS)-induced activation of microglia [16, 17] . However, whether triptolide could inhibit microglial activation and exert neuroprotective effect in 1-methyl-4-phenyl pyridinium (MPP + )-induced hemiparkinsonian rats still remain unknown.
The aim of the present study was, first, to evaluate the activation profile of microglia in MPP + -induced hemiparkinsonian rats, an ideal animal model of PD [18] . Then, we sought to investigate the effect of triptolide on microglial activation, and examined whether it could exert neuroprotective effect against MPP + neurotoxicity. [19] . For intranigral microinjection, a small hole was drilled in the skull above the left SN (5.0 mm anteroposterior, 2.1 mm lateral). A microsyringe was then lowered (7.7 mm dorsoventral), and 10 μg of MPP + (Sigma, USA) (5 μg/μL) in a saline buffer was infused at a rate of 0.4 μL/min for 5 min. After infusion of the toxin, the probe was kept in the same position for a further 5 min for complete diffusion of the drug and then slowly retracted. The post-operative animals were left in a temperature-controlled chamber until they recovered from anesthesia, then they returned to their home cages. . Administration of triptolide was principally consistent with the method described previously [17] . Briefly, triptolide was dissolved in saline containing 5% dimethylsulphoxide and applied intraperitoneally. Rats received a single dose of 5 μg/kg triptolide or vehicle per day from day 3 before MPP + injection and continued for 21 d post-lesion (24 d in total).
Materials and methods

Animals
Administration of triptolide
Behavioral tests
The degree of damage to nigrostriatal pathway can be assessed using sensitive drug and non-drug tests. A series of tests was performed before and on day 1, 3, 7, 14 and 21 after surgery.
Rotational behavior analysis
At all the above mentioned time points, rats were injected subcutaneously with 0.3 mg/kg apomorphine hydrochloride (Sigma, USA) dissolved in 0.1% ascorbate saline solution and allowed to sit in a separate cage for 15 min. Animals were then placed in an iron bowl, and the net number of turns (made towards the side of lesion minus those made away from the lesioned side) in a 30-min trial was calculated [20] .
Forelimb akinesia (stepping test)
Movement initiation for each limb was assessed using the forelimb akinesia test protocol [21] [22] [23] . In short, the rat was hold by the experimenter with one hand fixing the hindlimbs and slightly raising the hind part above the surface. The animal was allowed to initiate stepping movements in a 10 s period for the left forelimb and then the right one for a balanced order. An ipsilateral asymmetry score was derived [(ipsilteral steps/ipsilateral plus contralateral steps) -(contralateral steps/ipsilateral plus contralateral steps)].
Vibrissae-elicited forelimb placing
A vibrissae-elicited forelimb-placing test was used to test reaction to sensory stimuli as described previously [22] [23] [24] [25] . At the assigned time points after surgery, rats were gently held by their torsos with the forelimbs hung free. The respective vibrissae of the animal were brushed against the corner edge of a countertop to elicit a forelimb placing response from the forelimb on the same side. Intact animals place the forelimb of both sides quickly onto the countertop. Animals with unilateral damage will show varying degrees of impaired limb placing ability, while still placing the unimpaired limb reliably. Each animal was tested 10 times on each side. Percentage of unsuccessful placing responses was determined [(number placed contralaterally divided by the number placed ipsilaterally) ×10].
Immunohistochemistry and quantification
As previously described by our group [26] , rats were given an overdose of urethane (2 g/kg, i.p.) and perfused intracardially with 100 mL 0.9% saline followed by 400 mL cold 4% paraformaldehyde in 0.1 mol/L phosphate buffer (PB, pH 7.4). Brains were removed and immersed from 10%-30% gradient sucrose in PB for 24-48 h at 4 °C for cryoprotection. Coronal brain sections (free-floating, 30 μm) were cut by a freezing microtome (Leica 1900, German) and processed for immunofluorescence. All the sections were blocked with 10% normal donkey serum in 0.01 mol/L phosphate buffered saline (PBS, pH 7.4) with 0.3% Triton-X-100 for 1 h at room temperature and incubated over night at 4 °C with mouse anti-OX-42 (1:1000, Sigma, USA), rabbit anti-tyrosine hydroxylase (TH) (1:1000, Sigma, USA) primary antibody. The sections were then incubated with fluorescein isothiocyanate (FITC)-conjugated donkey antimouse IgG (1:200, Chemicon, USA) or rhodamine-conjugated donkey anti-rabbit IgG (1:200, Chemicon, USA) for 90 min at 4 °C, then washed in PBS. Omission of primary antibody served as negative control. The stained sections were examined with a Leica fluorescence microscope, and images were captured with a CCD spot camera. Because the morphology of microglia is complex and the immunoreactive staining includes both cell bodies and their processes, cell counts may not sufficiently quantify activation. Therefore, the integrated densities (pixelwise integration of density) of OX-42 immunoreactivity (OX-42-IR) within the SN were measured with the Leica Qwin 500 image analysis system (Germany) at six randomly selected sections for each animal.
Quantification of viable dopaminergic neurons were principally consistent with a method previously descried by Vaananen AJ et al. with slight modifications [27] . 
Results
Intranigrally injected MPP + induced microglial activation and dopaminergic neuronal loss in the SN area of rats
Activated microglia have been implicated in PD [10, 28] . thick and short lamellipodia (Fig. 1A) , which was consistent with previous studies [29] . The density of OX-42-IR significantly increased at day 3 post-lesion (t = 2.867, P < 0.05), and reached the peak at day 7 (t = 7.046, P < 0.05). At day 14 and day 21 post-lesion, the increase in OX-42-IR became less marked (t = 5.050, P < 0.05; t = 4.186, P < 0.05; Fig. 1B ).
Intranigral MPP + injection induced ongoing reduction of dopaminergic neurons as assessed by their expression of TH in SN ipsilateral to the MPP + injection site (Fig. 1C) Our results are broadly in accordance with previous study by Banerjee R et al. who showed that intranigral MPP + infusion cause long-lasting damage to the nigrostriatal dopamine pathway, and did not show any sign of recovery in striatal dopamine content even after 90 d [31] .
Triptolide attenuated MPP
+ -induced microglial activation and dopaminergic neuronal loss According to previous studies, triptolide is a potent anti-inflammatory and immunosuppressive agent, and is capable of inhibiting LPS-induced microglial activation and dopaminergic neuronal loss [13, 16] .
Here, we extended these studies to examine whether triptolide (Fig. 3A, B) .
The percentage of TH-positive neurons decreased in the SN ipsilateral to the MPP + injection site as compared with the contralateral side at day 21 post-lesion (t = 11.008, P < 0.05). Triptolide provided partially neuroprotection against dopaminergic neuronal loss as indicated by a much higher percentage of TH-positive neurons in the triptolide treatment group compared with the MPP + group (t = 3.050, P < 0.05; Fig.3A,   C ). In the vehicle treatment group of rats, the density of OX-42-IR and the percentage of TH-positive neurons were principally not different from the MPP + group (t = 0.078, P = 0.939; t = 0.421, P = 0.683; Fig. 3B, C) .
Triptolide mitigated behavioral abnormalities in MPP
+ intoxicated rats Since triptolide was capable of preserving dopaminergic neurons from MPP + -induced cell death, we then further our study to investigate whether triptolide could attenuate MPP + -induced behavioral defects in rats.
As shown in previous sections, intranigral injection of MPP + resulted in progressive locomotor disabilities. In rats treated with triptolide, there was a noticeable attenuation of behavioral defects between 7 to 21 d (Fig. 4) . Two-way ANOVA revealed significant effect of triptolide treatment (rotational behavior: Such results are consistent with the suggestion that anti-inflammatory and immunosuppressive agents are neuroprotective and may improve motor function in PD animals [32, 33] . In the vehicle treated group, the behavioral defects were not ameliorated compared with the MPP + group at all the time points observed.
Discussion
The search for neuroprotective agents in PD is primarily based on the ability of a specific drug to reduce dopaminergic neuronal loss. Agents that can provide such neuroprotective effects have the potential to become novel therapeutics to PD [4, 5] . Existing animal models of PD provide us with useful tools to test new neuroprotective agents and strategies. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite, MPP + , represent ideal neurotoxins that can replicates most features of sporadic PD in various animals [35] . However, if MPTP is systemically administered, not only dopaminergic neurons but also other cell types, particularly the glial cells will be affected simultaneously [29] . Because the enzymatic conversion of MPTP to MPP + by monoamine oxidase (MAO)-B mainly occurs in astrocyte [35] [36] [37] , and drugs that can increase MAO activity have been shown to aggravate the neurotoxicity of MPTP by producing more MPP + [29, 36] , study of neuroprotective agents using MPTP model of PD is open to multiple interpretations including the influence of astrocyte by the drugs tested. The MPP + -induced hemiparkinsonian rats, thus, can be used as a reliable tool to understand the pathogenic relationships between microglial reaction and dopaminergic neurons, without having to concern about possible interference of astrocyte-neuron interaction. After MPP + enters into dopaminergic neurons through dopamine transporter (DAT), it is concentrated within the mitochondria and inhibit complex I activity, which leads to the decrease in ATP content and bring widespread damage to neurons. The inhibition of complex I is considered as the "primary injury" to dopaminergic neurons [38, 39] . However, more attention have recently been drawn to the "secondary damage" to neurons caused by inflammatory processes which have been suggested to have a major impact on the progressive dopaminergic cell death in PD [38] [39] [40] .
The hallmark of neuroinflammation in PD is the activation of microglia. From a neuropathological standpoint, microglial activation is indicative of an active, ongoing process of cell death [40, 41] . Activated microglia not only bring damage to neurons through releasing a variety of noxious compounds [42, 43] , but also recruit and activate more microglial cells, forming a vicious cycle that leads to more dopaminergic neuronal death. In the present study, after MPP + intoxication to SN, we observed a progressive TH-positive cell loss and behavioral defects in rats, which were consistent with previous studies [23, 31, 44] . Activation of microglia was seen from the third day after MPP + injection and lasted throughout our experiment. Together with the suggestion that in the etiology of PD, activation of microglia represent an important cause of dopaminergic neuronal death [7, 39] , so it is postulated that microglia inhibitors might protect dopaminergic cell from injury induced by PD neurotoxins.
Extracts of the herb TWHF have been used for over two centuries as Traditional Chinese Medicine (TCM) to treat a variety of inflammatory and autoimmune diseases. Most of the pharmacological activity of TWHF can be attributed to triptolide and its most abundant and active component [14, 45] .
Here, we showed that chronic administration of triptolide decreased the immunodensity of OX-42, attenuated TH-positive neuronal loss and ameliorated the behavioral abnormalities in MPP + -induced hemiparkinsonian rats. Our results are in agreement with previous reports, wherein triptolide inhibits LPS-induced microglial activation and dopaminergic neuronal loss [13, 16, 17] , providing further evidence for the involvement of microglia in PD pathogenesis and the therapeutic potential for microglia inhibitors.
One of the possible mechanisms underlying the pharmaceutical effect of triptolide may be suppressing the expression of cyclooxygenase-2 (Cox-2), a specific proinflammatory factor which has emerged as an important mediator of microglial activation [40] . Neurons expressing COX-2 would cause their own demise through a harmful interplay with microglia [46] [47] [48] . Studies using COX-2 knockout mice and COX-2 inhibitors demonstrated reduced microglial activation and attenuated dopaminergic cell loss in PD models [40, 49, 50] . Since triptolide have been suggested to inhibit COX-2 expression in a variety of settings [14, 51] , further researches are warranted to determine whether triptolide exerts its inhibitory effect on microglial activation in MPP + rat model of PD through modulating COX-2 expression. It is also worth mentioning that inhibition of microglia by triptolide, as used here, only partially blocked the dopaminergic cell death, suggesting that other mechanisms independent of microglia-related neuronal damage are also involved in MPP + neurotoxicity. As mentioned above, after MPP + is taken up by dopaminergic neurons, it is concentrated in mitochondria and inhibits complex I, resulting in ATP depletion and subsequent cell death [52] . Thus, the inhibition of complex I may account for another aspect of the disease phenotype which can not be ameliorated by microglia inhibitors. Although this possibility cannot be confirmed with certainty, our observation that inhibition of microglia by triptolide preserve only a part of TH-positive neurons from injury rather support the view that dopaminergic neurons are damaged through more than one mechanism.
In summary, our result support the involvement of microglia in the progressive dopaminergic neuronal loss in MPP + rat model of PD. Triptolide exerted neuroprotective effect on MPP + -induced dopaminergic neuronal injury and attenuated behavioral disabilities. Suppression of microglial activation may, at least in part, account for the mechanism underlying the neuroprotective effect of triptolide. Control of microglia-related neuroinflammation, thus, may represent a promising therapeutic strategy in the future management of PD.
